Palisade Bio (PALI) EBITDA (2010 - 2026)

Palisade Bio (PALI) has 17 years of EBITDA data on file, last reported at -$10.7 million in Q1 2026.

• On a quarterly basis, EBITDA fell 365.28% year-over-year to -$10.7 million in Q1 2026; TTM through Mar 2026 was -$26.5 million, a 96.31% decrease from a year earlier, with the FY2025 full-year figure at -$18.1 million, down 21.52% from the prior year.
• EBITDA for Q1 2026 stood at -$10.7 million, down from -$10.0 million in the prior quarter.
• Over the last five years, EBITDA for PALI reached as high as -$2.3 million in Q1 2025 and fell as low as -$10.7 million in Q1 2026.
• Historically, EBITDA has averaged -$4.3 million across 5 years, with a median of -$3.6 million in 2023.
• Across the five-year window, EBITDA surged 89.13% in 2022 and plunged 365.28% in 2026, its largest moves.
• Year by year, EBITDA stood at -$3.8 million in 2022, then gained by 18.04% to -$3.2 million in 2023, then decreased by 7.23% to -$3.4 million in 2024, then slumped by 195.12% to -$10.0 million in 2025, then decreased by 7.68% to -$10.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.